A Superphane-based carcerand for arsenic detoxification via imprisoning arsenate
Source abstract
Abstract
Carcerands, special molecular constructs with enclosed interiors as a new phase of matter, have attracted immense interest because of their unique structures, physicochemical properties, and potential applications in many aspects, e.g., targeted drug delivery. However, carcerands for imprisoning, inter alia, anions of interest represent an unmet challenge. Herein, we report the design and synthesis of a superphane-based carcerand 1, featuring up to 18 anion binding sites and a fully enclosed interior space. Carcerand 1 is found capable of incarcerating H2PO4− anion, yielding an anion carceplex 5, as inferred from crystallographic analysis, 1H nuclear magnetic resonance (NMR) spectroscopy, and diffusion-ordered NMR spectroscopy (DOSY), as well as molecular dynamics simulations. More importantly, highly toxic arsenate anion was also imprisoned within carcerand 1, offering the arsenate carceplex 6 that proved nontoxic compared with free arsenate or peripherally bound arsenate in the HEK293T cell line.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Molecular Sensors and Ion Detection · Arsenic contamination and mitigation · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (45)
Show source-provided references
1. Arsenic and human health effects: a review10.1016/j.etap.2015.09.016 ↗
2. The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects10.1016/S1040-8428(01)00215-3 ↗
3. The ecology of arsenic10.1126/science.1081903 ↗
4. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia10.1056/NEJMoa1300874 ↗
5. Arsenic trioxide controls the fate of the PML–RAR alpha oncoprotein by directly binding PML10.1126/science.1183424 ↗
6. Arsenic trioxide for the treatment of myelodysplastic syndromes10.1517/14656566.5.3.613 ↗
7. Arsenic trioxide in multiple myeloma: rationale and future directions10.1097/00130404-200201000-00003 ↗
8. Effects and mechanism of arsenic trioxide in combination with rmhTRAIL in multiple myeloma10.1016/j.exphem.2015.10.004 ↗
9. Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors10.1002/med.21844 ↗
10. Arsenic–protein interactions as a mechanism of arsenic toxicity10.1016/j.taap.2021.115738 ↗
11. Incorporation of an internal ribosome entry site–dependent mechanism in arsenic–induced GADD45 alpha expression10.1158/0008-5472.CAN-07-0867 ↗
12. Current advances of nanomedicines delivering arsenic trioxide for enhanced tumor therapy10.3390/pharmaceutics14040743 ↗
13. Therapeutic potential of delivering arsenic trioxide into HPV–infected cervical cancer cells using liposomal nanotechnology10.1186/s11671-016-1307-y ↗
14. A novel RGDyC/PEG co–modified PAMAM dendrimer–loaded arsenic trioxide of glioma targeting delivery system10.2147/IJN.S175418 ↗
15. Recent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancers
16. Ferritin–based targeted delivery of arsenic to diverse leukaemia types confers strong anti–leukaemia therapeutic effects10.1038/s41565-021-00980-7 ↗
17. Characterization of cavities in carcerands10.1351/pac199365030539 ↗
18. Cram · 1997
19. Carcerands and hemicarcerands
20. 6.06 – carcerands and hemicarcerands
21. A calix[4]arene carceplex with four Rh–2(4+) fasteners10.1021/ja0396899 ↗
22. Current status and future developments of endohedral metallofullerenes10.1039/c2cs35214a ↗
23. Endohedral metallofullerenes: new structures and unseen phenomena10.1002/chem.201905306 ↗
24. Carcerands
25. Warmuth · 2010 · 227
26. Carcerands and hemicarcerands
27. Reversible photochemically gated transformation of a hemicarcerand to a carcerand10.1002/anie.201205376 ↗
28. Self–assembled carcerand–like cage with a thermoregulated selective binding preference for purification of high–purity C–60 and C–7010.1021/acs.joc.8b02674 ↗
29. Advances in anion supramolecular chemistry: from recognition to chemical applications10.1002/anie.201309937 ↗
30. Applications of supramolecular anion recognition10.1021/acs.chemrev.5b00099 ↗
31. Macrocycles as ion pair receptors10.1021/acs.chemrev.8b00734 ↗
32. Chloride capture using a C–H hydrogen–bonding cage10.1126/science.aaw5145 ↗
33. Strapped calix[4]pyrroles: from syntheses to applications10.1039/C9CS00528E ↗
34. Efficient and selective uptake of TcO(4)(–) by a cationic metal–organic framework material with open Ag(+) sites10.1021/acs.est.7b00339 ↗
35. Identifying the recognition site for selective trapping of (99)TcO(4)(–) in a hydrolytically stable and radiation resistant cationic metal–organic framework10.1021/jacs.7b08632 ↗
36. [2.2.2.2.2.2](1,2,3,4,5,6)Cyclophane: superphane10.1021/ja00505a053 ↗
37. [2n]Cyclophanes: paracyclophane to superphane10.1021/ar50147a001 ↗
38. “Super” phanes10.1021/ar00030a003 ↗
39. Superphanes10.1002/3527603964.ch4 ↗
40. Superphane: a new lantern–like receptor for encapsulation of a water dimer10.1039/D1CC01158H ↗
41. Superphanes: facile and efficient preparation, functionalization and unique properties10.1016/j.tchem.2022.100006 ↗
42. A highly selective superphane for ReO4− recognition and extraction
43. A hexapodal capsule for the recognition of anions10.1021/jacs.0c12329 ↗
44. Picking on carbonate: kinetic selectivity in the encapsulation of anions10.1002/anie.202116518 ↗
45. Multiwfn: a multifunctional wavefunction analyzer10.1002/jcc.22885 ↗